- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03806426
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this Phase III study is to determine whether Eicosapentaenoic acid-free fatty acid is a safe and well tolerated treatment in reducing the number of polypectomies FAP patients with an APC gene mutation have over a 2 year treatment period and to assess the effect that this has on clinical disease progression. Planned Sample Size This study will enrol 204 subjects (102 subjects per treatment group). Primary Objective is to determine the efficacy of EPA-FFA gastro-resistant capsules in patients with FAP in reducing polypectomy.
Secondary objectives is to evaluate the clinical disease progression and the long-term safety and tolerability of EPA-FFA.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Justin Slagel, CEO
- Phone Number: +44 1923 681001
- Email: info@slapharma.com
Study Locations
-
-
-
Bologna, Italy, 40138
- University of Bologna and St.Orsola-Malpighi Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Must give written informed consent.
- Male or female subjects, 18 to 65 years of age.
- Known diagnosis of FAP defined as those with a pathogenic APC mutation
- Patients have had a previous colectomy with an ileo-rectal anastomosis or an ileal pouch- anal anastomosis with a rectal remnant of ≥ 2cm.
- Classified stage 1-3 on InSiGHT Polyposis Staging System (IPSS).
- Subjects must show a willingness to abstain from regular use of non-steroidal anti-inflammatory medication for the trial. A cardio protective dose of aspirin (75mg-100mg) will be permitted.
Exclusion Criteria:
- Subjects with ileo-rectal anastomosis who have ≥ 20 polyps which are of >5mm that are not amendable to removal in the rectum.
- Subjects unwilling to have regular sigmoidoscopy examination.
- Subjects who are due to undergo gastro-intestinal surgery related to FAP.
- History of invasive carcinoma in the past 3 years.
- History of pelvic radiation.
- Known allergic reaction or intolerant to fish or fish oils.
- Known allergic reaction to excipients of IMP and placebo.
- Subjects who are pregnant or breast-feeding at screening.
- Subjects taking aspirin, other than a low (75mg-100mg) cardioprotective dose on a regular basis, or other nonsteroidal anti-inflammatory drugs (NSAIDs) on a regular basis. Regular use of other NSAIDS is defined in this protocol as use greater than 14-day treatment period, and one treatment per six months for the duration of the study.
- Subjects taking NSAIDs regularly in the 3 months prior to entry (other than low dose aspirin).
- Subjects taking NSAID, 5-aminosalicylic acid (5-ASA or mesalamine).
- Subjects who are taking other fish-oil supplements (e.g. cod liver oil) who are unwilling to stop them for the duration of the study. Subjects previously taking fish oil must have a washout period of 2 months prior to study enrolment.
- Subjects who are taking warfarin or other anticoagulants.
- Experimental agents must have been discontinued at least 8 weeks prior to screening or for a period equivalent to 5 half-lives of the agent (whichever is longer).
- Subjects suffering from known disorders of clotting and blood coagulation.
- Subjects who have significant abnormalities on their screening blood tests.
- Subjects with gastrointestinal malabsorptive disease.
- Subjects with uncontrolled hypercholesterolaemia.
- Subjects who are deemed mentally incompetent or have a history of anorexia nervosa or bulimia.
- Subjects who will be unavailable for the duration of the trial, deemed unable to comply with the requirements of the study protocol, likely to be noncompliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason.
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless surgically sterile, must use effective contraception (either combined oestrogen and progestogen containing hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD], intrauterine hormone-releasing system [IUS], vasectomised partner, sexual abstinence (only considered an acceptable method of contraception when it is in line with the subjects' usual and preferred lifestyle), combination of male condom with either cap, diaphragm or sponge with spermicide [double barrier methods]), and willing and able to continue contraception for 1 month after the last administration of IMP.
- Women using oral contraception must have started using it at least 2 months prior to screening. Women are not considered to be of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels that have been confirmed to be in the "postmenopausal range". Or have had a surgical bilateral oophorectomy (with or without hysterectomy) or bilateral tubal ligation at least six weeks before the screening visit. In case of oophorectomy alone, the reproductive status of the woman should have been confirmed by follow up hormone level assessment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Group A
Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg
|
500mg capsule, two 500mg capsules to be taken twice daily for 24 months
Other Names:
|
Placebo Comparator: Treatment Group B
Placebo 500mg
|
500mg capsule, two 500mg capsules to be taken twice daily for 24 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Number of Polypectomies (polyps > 5mm in the rectum) conducted during the 24 months study period
Time Frame: 24 months
|
Proctectomy is indicated when polyp burden is frequently high in the remaining rectum, if large highly dysplastic polyps occur, or if frank malignancy develops.
Proctocolectomy also significantly reduces the cancer risk with the removal of the colon and rectum.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Polyp number at 24 months assessed by blinded review of video records
Time Frame: 24 months
|
Subsequent proctectomy is indicated when polyp burden is frequently high in the remaining rectum, if large highly dysplastic polyps occur, or if frank malignancy develops.
Proctocolectomy also significantly reduces the cancer risk with the removal of the colon and rectum.
|
24 months
|
Change in score on the InSIGHT Polyposis Staging System (IPSS) at 24 months
Time Frame: 24 months
|
Classified stage on InSiGHT Polyposis Staging System (IPSS). The subjects FAP will be classified in accordance with the IPSS. The IPSS classification will be verified by the Polyp Video Scoring committee |
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Luigi Ricciardiello, MD, Associate Professor of Gastroenterology, University of Bologna
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Syndromes, Hereditary
- Adenomatous Polyps
- Adenoma
- Intestinal Polyposis
- Nasopharyngeal Neoplasms
- Colorectal Neoplasms
- Adenomatous Polyposis Coli
Other Study ID Numbers
- EPA-POL-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial Adenomatous Polyposis
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedFamilial Adenomatous Polyposis (FAP)Italy
-
M.D. Anderson Cancer CenterCompletedAttenuated Familial Adenomatous Polyposis | Deleterious Familial Adenomatous PolyposisUnited States
-
PfizerTerminatedFamilial Adenomatous Polyposis (FAP)United States, Spain, Canada, Denmark
-
National Cancer Institute (NCI)CompletedFamilial Adenomatous Polyposis | Attenuated Familial Adenomatous PolyposisUnited States, Puerto Rico
-
S.L.A. Pharma AGCompletedFAP | Familial Adenomatous Polyposis ColiUnited Kingdom
-
michal rollUnknownFAP-Familial Adenomatous PolyposisIsrael
-
National Cancer Institute (NCI)RecruitingFamilial Adenomatous Polyposis | Colorectal Carcinoma | Attenuated Familial Adenomatous Polyposis | Duodenal CarcinomaUnited States, Puerto Rico
-
Copenhagen University Hospital, HvidovreCompletedDuodenal Cancer | Duodenal Polyposis | Familial Adenomatous PolyposesDenmark
-
michal rollUnknownFAP-Familial Adenomatous Polyposis
-
Dr. Ersin Arslan Education and Training HospitalCompleted
Clinical Trials on Eicosapentaenoic acid free fatty acid (EPA-FFA)
-
Karadeniz Technical UniversityUnknown
-
Thomas Jefferson UniversityGlaxoSmithKline; Drexel UniversityUnknownQuality of Life | Inflammation | Sickle Cell Disease | HEMOGLOBIN SS | Hemoglobin S Beta-0 ThalassemiaUnited States
-
Penn State UniversityUnited States Department of Agriculture (USDA)CompletedInflammation | Cardiovascular DiseaseUnited States
-
Mayo ClinicCompletedObesity | Barrett's EsophagusUnited States
-
Massachusetts General HospitalEmory UniversityCompletedInflammation | Overweight | Major Depressive DisorderUnited States
-
Samuel FortinTerminated
-
University of LeedsCompletedColorectal CancerUnited Kingdom
-
Gregor BergerSwiss National Science FoundationCompleted
-
Wake Forest University Health SciencesTerminatedBrain Health | Brain Function | Brain DevelopmentUnited States